SCHEMBL19301633

SCHEMBL19301633

Cc1ncc(-c2ccccc2)n1CC1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ CDK2 P24941 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HPGDS O60760 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ PDE6D O43924 1/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ AXL P30530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19419968 0.78 KDM4E (0.47) TDP1CYP1A2CYP3A4CYP2D6MEN1
SCHEMBL19284413 0.76 ALDH1A1 (0.44) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL19301627 0.76 KDM4E (0.43) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL19301779 0.76 NOTUM (0.41) MEN1KMT2APKMALDH1A1LMNA
SCHEMBL10616089 0.73 TSHR (0.58) TDP1CYP1A2CYP3A4CYP2D6MEN1
SCHEMBL19301734 0.73 KDM4E (0.40) TDP1MEN1KMT2AALDH1A1LMNA
SCHEMBL3018678 0.72 KDM4E (0.40) TDP1CYP1A2CYP3A4CYP2D6MEN1
SCHEMBL4030274 0.72 CDK2 (0.54) CDK2ALDH1A1MAPTKDM4E
SCHEMBL19301723 0.70 ABCC1 (0.43) CYP3A4MEN1KMT2AALDH1A1LMNA
SCHEMBL19284316 0.69 ALDH1A1 (0.38) TDP1ALDH1A1LMNAL3MBTL1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2021-12-14 — — US disclosed
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS INC (US) 2021-06-24 — — US disclosed
WO-2017147102-A1 HETEROARYL INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. (US) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188810-A1 HETEROARYL INHIBITORS OF PAD4 PADI4, PADI1, PADI6 TDP1 22/4885CYP1A2 1796/4885CYP3A4 988/4885
US-11198681-B2 Heteroaryl inhibitors of PAD4 PADI4, PADI1, PADI6 TDP1 22/4885CYP1A2 1796/4885CYP3A4 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback